Lomefloxacin  (Synonyms: SC47111A; NY-198)

Lomefloxacin (SC47111A) is an orally active difluoroquinolone antibiotic. Lomefloxacin prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin induces ROS production and Apoptosis. Lomefloxacin has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin has anticancer effects against melanoma. Lomefloxacin can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma ^{[1][2][3][4][5][6]}.

Lomefloxacin (1/4 to 2×MIC concentrations) rapidly reduces viable cell counts of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, with no regrowth observed in all strains except P. aeruginosa^[1].
Lomefloxacin exhibits MIC values ranging from 0.06-4 μg/mL in susceptibility determination experiments with strains such as Escherichia coli and Staphylococcus aureus^[2].
Lomefloxacin (0.1-1.0 mM; 24-72 h) decreases viability of COLO829 cells and induces ROS production in COLO829 cells^[3].
Lomefloxacin (50-100 μM) induces apoptosis in keratinocyte^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lomefloxacin (ED₅₀: 1.45-32.2 mg/kg; p.o.; immediately after infection) significantly reduces mortality in mice with intraperitoneal infection models, with ED₅₀ values lower than those of Ofloxacin and Norfloxacin^[1].
Lomefloxacin (-80 mg/kg; orogastric administration) reduces mortality, significantly decreases splenic bacterial counts, and inhibits inflammatory response in mice infected with Salmonella typhimurium^[5].
Lomefloxacin (16-32 mg/kg; i.p.; 5 days) only at the highest dose slightly reduces the number of implants and live fetuses in the third week of mating in mice, without significant dominant lethal mutation induction^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

351.35

C₁₇H₁₉F₂N₃O₃

98079-51-7

Solid

White to off-white

O=C(C1=CN(CC)C2=C(C=C(F)C(N3CC(C)NCC3)=C2F)C1=O)O

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Hirose T, et al. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother. 1987 Jun;31(6):854-9.  [Content Brief]

  [2]. Piddock LJ, et al. Mechanism of action of lomefloxacin. Antimicrob Agents Chemother. 1990 Jun;34(6):1088-93.  [Content Brief]

  [3]. Beberok A, et al. Lomefloxacin Induces Oxidative Stress and Apoptosis in COLO829 Melanoma Cells. Int J Mol Sci. 2017 Oct 20;18(10):2194.  [Content Brief]

  [4]. Marrot L, et al. Molecular responses to photogenotoxic stress induced by the antibiotic lomefloxacin in human skin cells: from DNA damage to apoptosis. J Invest Dermatol. 2003 Sep;121(3):596-606.  [Content Brief]

  [5]. Butler T, et al. Treatment of experimental Salmonella typhimurium infection in mice with lomefloxacin. J Antimicrob Chemother. 1990 Apr;25(4):629-34.  [Content Brief]

  [6]. Singh AC, et al. Genotoxicity of lomefloxacin--an antibacterial drug in somatic and germ cells of Swiss albino mice in vivo. Mutat Res. 2003 Feb 5;535(1):35-42.  [Content Brief]